Drug Discovery

#Drug development

Funding boost for tech that translates novel plant molecules into medicines

Enveda Biosciences’ $4.9 million seed round of funding will enable the company to grow its medicinal plant dataset, enhance its technologies and algorithms to accelerate natural product drug discovery and advance its lead asset for liver fibrosis through preclinical development. The funding was led by True Ventures, with participation from… Read More

#News

#Drug development #Drug discovery #Therapeutics

Small molecule therapeutics: solubility with permeability to achieve better bioavailability

Technologies have been honed to overcome many of the challenges of administering BCS class II and IV small molecule therapeutics says John S. Vrettos, Senior Principal Scientist & Head of Formulation Development, Enteris BioPharma Small molecule drugs have traditionally dominated the treatment of human disease given their diverse mechanisms of… Read More

#Exclusive Content

#Biologics #Drug development #Drug discovery #Oncology #Therapeutics

International consortium awarded grant for first-in-class metastatic cancer treatment

ONA Therapeutics, Absolute Antibody and RIC – three leading European companies in the biotech landscape – have been awarded a Eurostars grant for a two-year project that will develop a proprietary biological drug with a unique mode of action for the treatment of various types of metastatic cancers. Taking the… Read More

#Cancer Research #News

#Drug development #Drug discovery #Target validation

Evotec milestones in Bristol Myers Squibb collaboration

Evotec has achieved key milestones in its partnership with Bristol Myers Squibb in the field of targeted protein degradation with the first two targets transitioning into drug discovery after completing a comprehensive target validation process. Evotec and Bristol Myers Squibb (the successor in interest to Celgene) initiated their long-term strategic… Read More

#News

#Biotechnology #Drug development #Drug discovery #Health #Life sciences #Narrated podcasts #Pharmaceutical

2030 Life Sciences and Health in the Digital Age (Part 1)

This article is the first in a two-part series based on The Pistoia Alliance report. Written in retrospect from the world as it is in 2030, it looks at how healthcare has changed in the intervening decade, covering the socio-economic and political evolutions that have happened, the subsequent effects on… Read More

#Podcasts

#Drug development

Galapagos and Gilead Sciences in new agreement

Gilead Sciences and Galapagos have agreed to amend their existing arrangement for the commercialisation and development of Jyseleca (filgotinib). This announcement follows a meeting with the US FDA related to the New Drug Application (NDA) for filgotinib in the treatment of rheumatoid arthritis (RA.) Based on the feedback received from the… Read More

#News

#Antibody #Biologics #Drug discovery #High throughput screening

PerkinElmer invests in Carterra, antibody screening and characterisation expert

Carterra, specialist in label-free high throughput antibody screening and characterisation, has closed on a round of equity financing led by PerkinElmer. Current Carterra investors Telegraph Hill Partners and Ballast Point Ventures also participated in the financing round. The Carterra LSA platform for accelerating the discovery of therapeutic antibodies has become… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #Antibodies #Biotechnology #Cancer research #Drug development #Oncology

AI-driven precision medicine for development of HMBD-001 in HER3-driven cancers

Hummingbird Bioscience, a clinical-stage biotech company focused on developing revolutionary therapies for hard-to-drug targets, is collaborating with Tempus, an expert in artificial intelligence and precision medicine. This will drive the development of Hummingbird’s lead clinical program, HMBD-001, as it advances into clinical trials in HER3-driven cancers, including those that harbour… Read More

#Cancer Research #News

#Drug development #Immune system

Schizophrenia may be similar to immune disorders, say scientists

A study by clinical scientists at The University of Manchester has shown that schizophrenia may – in some part – be caused by disordered functioning of the immune system. The first ever trial in schizophrenia of the powerful immune suppressant drug, Methotrexate, produced what the team described as ‘promising’ effects… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #Biomarkers #Drug discovery

2020 overview for AI for drug discovery, biomarker development and advanced R&D

Deep Pharma Intelligence announces the release of a new, open-access 130-page analytical report and interactive analytics Dashboard: AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview 2020. This delivers advanced market intelligence, interactive mindmaps, benchmarking for companies, investors and technologies, competitive and SWOT analysis through the interactive IT-Platform and… Read More

#Editor's Choice #Market Reports #News

#Assay development & optimisation #Drug discovery

Event for assay developers, screening scientists and drug discovery research scientists

We understand the importance of kinetic assay design. In the upcoming DDW collaboration, supported by SPT Labtech, Dr Nick Holliday, Chief Scientific Officer, Excellerate Bioscience, will share his pharmacology expertise to explain how to produce assays that deliver hits with higher physiological relevance. Due to popularity we have opened up… Read More

#Editor's Choice #News

#Drug discovery #Drug targets

Webinar: Hit discovery for trained immunity and tolerance

Do you want to learn about: Trained immunity The role of epigenetic targets in trained immunity Hit discovery through ultra-high throughput screening of large libraries Industry standard Hit-to-Lead biological profiling frameworks Join Dr. Saman Honarnejad, Director Drug Discovery at Pivot Park Screening Centre​ on 14 December 3PM (GMT) for this… Read More

#News

#Biologics / Biotechnology #Biomanufacturing #Cell therapy #Drug development

Cedars-Sinai biomanufacturing centre spurs cell therapies to help develop new drugs

Cedars-Sinai has launched a centre to manufacture the next generation of stem cell and gene therapies that will enable biomedical researchers, government medical programs, commercial entities and others to develop new biologic drugs and propel novel disease discoveries. Biologic drugs are produced from living organisms or contain components of living… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #Biologics #Drug development

IDBS Polar launch streamlines biopharmaceutical development

IDBS has launched Polar biopharma lifecycle management (BPLM),  which is aimed at streamlining drug development and manufacturing in biopharma research. The development of biologics is a dynamic process and those who are most successful must be able to adapt to changes in process or technology rapidly. IDBS data has found… Read More

#News